Familial Combined Hyperlipidemia: Controversial Aspects of its Diagnosis and Pathogenesis

Carlos A. Aguilar Salinas; Margarita Zamora; Rita A. Gómez-Díaz; Roopa Mehta; Francisco J. Gómez Pérez; Juan A. Rull

doi:10.1055/s-2004-835379

Seminars in Vascular Medicine, Table of Contents

Semin Vasc Med 2004; 4(2): 203-209
DOI: 10.1055/s-2004-835379

Familial Combined Hyperlipidemia: Controversial Aspects of its Diagnosis and Pathogenesis

Carlos A. Aguilar Salinas¹ , Margarita Zamora¹ , Rita A. Gómez-Díaz¹ , Roopa Mehta¹ , Francisco J. Gómez Pérez¹ , Juan A. Rull¹

¹Departamento de Endocrinología y Metabolismo, Instituto Nacional de Ciencias Médicas y Nutrición, Mexico City, Mexico
²Servicio de Endocrinología Pediátrica, Hospital de Pediátrica, Mexico City, Mexico

Abstract

Familial combined hyperlipidemia is the most frequent cause of primary dyslipidemia in Mexico. Its manifestations include hypercholesterolemia, hypertriglyceridemia, or a combination of both. Despite its high frequency, a proper diagnosis is rarely made. Assessment of the lipid profiles of at least three first-degree relatives is necessary. The diagnosis of familial combined hyperlipidemia in a family not only leads to the identification of other affected family members but, more important, allows cardiovascular risk stratification of those affected. Prospective studies have confirmed the atherogenicity of the disease. A critical review of the current literature in this field is presented in this article. Although three screenings of the genome have been completed, the genes responsible for this disorder have not been identified. Limitations with respect to the characterization of affected subjects and the heterogeneity of the disease are among possible explanations. However, familial combined hyperlipidemia, because of its high prevalence, must be given greater priority. It represents a great challenge for physicians involved in the treatment of dyslipidemic patients.

KEYWORDS

Familial combined hyperlipidemia - apolipoprotein B - cholesterol - triglycerides - HDL cholesterol

Full Text

References

REFERENCES

1 Davignon J, Genest Jr J. Genetics of lipoprotein disorders. Endocrinol Metab Clin North Am. 1998; 27 521-550
2 Arner P. Is familial combined hyperlipidaemia a genetic disorder of adipose tissue?. Curr Opin Lipidol. 1997; 8 89-94
3 Bredie S J, Demacker P N, Stalenhoef A F. 1997. Metabolic and genetic aspects of familial combined hyperlipidaemia with emphasis on low-density lipoprotein heterogeneity. Eur J Clin Invest. 1997; 27 802-811
4 Goldstein J L, Schrott H G, Hazzard W T, Bierman E L, Motulsky A G. Hyperlipidemia in coronary heart disease. II: genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest. 1973; 52 1544-1568
5 Rose H G, Kranz P, Weinstock M, Juliano J, Haft J I. Inheritance of combined hyperlipoproteinemia: evidence for a new lipoprotein phenotype. Am J Med. 1973; 54 148-160
6 Nikkila E A, Aro A. Family study of serum lipids and lipoproteins in coronary heratheart disease. Lancet. 1973; 1 954-959
7 Erkelens D W. Metabolic basis for hypertriglyceridaemia in familial combined hyperlipidaemia. Eur Heart J. 1998; 19( suppl H) H23-H26
8 Grundy S M, Chait A, Brunzell J D. Familial Combined Hyperlipidemia Workshop. Arteriosclerosis. 1987; 7 203-207
9 Sniderman A D, Ribalta J, Castro Cabezas M. How should FCHL be defined and how should we think about its metabolic bases?. Nutr Metab Cardiovasc Dis. 2001; 11 259-273
10 Sniderman A D, Castro-Cabezas M, Riblata J et al.. A proposal to redefine familial combined hyperlipidemia-third workshop on FCHL. Eur J Clin Invest. 2002; 32 71-73
11 de Graaf J, Stalenhoef A F. Defects of lipoprotein metabolism in familial combined hyperlipidaemia. Curr Opin Lipidol. 1998; 9 189-196
12 Albers J J, Marcovina S M, Kennedy H, Mei J V, Henderson L O, Hannon W H. International Federation of Clinical Chemistry standardization project for measurement of apolipoproteinsA-I, and B. Comparability of apolipoprotein B values by use of International Reference Material. Clin Chem. 1994; 40 586-592
13 Bredie S J, Demacker P N, Stalenhoef A F. 1997. Metabolic and genetic aspects of familial combined hyperlipidaemia with emphasis on low-density lipoprotein heterogeneity. Eur J Clin Invest. 1997; 27 802-811
14 Valles V, Aguilar-Salinas C A, Gómez-Pérez F J et al.. Apolipoprotein B and AI distribution in the Mexican urban adults: results of a nation-wide survey. Metabolism. 2002; 51 560-568
15 McNeely M, Edwards K, Marcovina S, Brunzell J D, Motulsky A, Austin M. Lipoprotein and apolipoprotein abnormalities in familial combined hyperlipidemia: a 20-year prospective study. Atherosclerosis. 2001; 159 471-481
16 Kwiterovich P O. Clinical relevance of the biochemical, metabolic and genetic factors that influence low-density lipoprotein heterogeneity. Am J Cardiol. 2002; 90(suppl) 30i-47i
17 Aguilar-Salinas C A, Díaz-Polanco A, Quintana E et al.. Genetic factors play an important role in the pathogenesis of hyperlipidemia post-transplantation. Am J Kidney Dis. 2002; 40 169-177
18 Sniderman A D, Wolfson C, Teng B, Franklin F A, Bachorik P S, Kwiterovich P O. Association of hyperapobetalipoproteinemia with endogenous hypertriglyceridemia and atherosclerosis. Ann Intern Med. 1982; 97 833-839
19 Porkka K V, Nuotio I, Pajukanta P et al.. Phenotype expression in familial combined hyperlipidemia. Atherosclerosis. 1997; 133 245-253
20 Hokanson J, Austin M, Zambon A, Brunzell J. Plasma triglycerides and LDL heterogeneity in familial combined hyperlipidemia. Arterioscler Thromb. 1993; 13 427-434
21 Babirak S, Brown G, Brunzell J. Familial combined hyperlipidemia and abnormal lipoprotein lipase. Arterioscler Thromb. 1992; 12 1176-1183
22 Ascaso J F, Merchante A, Lorente R, Real J T, Martinez-Valls J, Carmena R. A study of insulin resistance using the minimal model in nondiabetic familial combined hyperlipidemic patients. Metabolism. 1998; 47 508-513
23 Meijssen S, Castro Cabezas M, Twickler T, Jansen H, Erkelens D W. In vivo evidence of defective postprandial and postabsorptive free fatty acid metabolism in familial combined hyperlipidemia. J Lipid Res. 2000; 41 1096-1102
24 Aouizerat B E, Allayee H, Cantor R M et al.. Linkage of a candidate gene locus to familial combined hyperlipidemia: lecithin:cholesterol acyltransferase on 16q. Arterioscler Thromb Vasc Biol. 1999; 19 2730-2736
25 Pei W, Baron H, Muller-Myhsok B et al.. Support for linkage of familial combined hyperlipidemia to chromosome 1q21-q23 in Chinese and German families. Clin Genet. 2000; 57 29-34
26 Pihlajamäki J, Rissanen J, Valve R, Heikkinen S, Karjalainen L, Laakso M. Different regulation of free fatty acid levels and glucose oxidation by the Trp64Arg polymorphism of the beta3-adrenergic receptor gene and the promoter variant (A-3826G) of the uncoupling protein 1 gene in familial combined hyperlipidemia. Metabolism. 1998; 47 1397-1402
27 Coon H, Myers R, Borecki I et al.. Replication of linkage of familial combined hyperlipidemia to chromosome 1q with additional heterogeneous effect of apolipoprotein A-I/C-III/A-IV locus. Arterioscler Thromb Vasc Biol. 2000; 20 2275-2280
28 Venkatesan S, Cullen P, Pacy P, Halliday D, Scott J. Stable isotopes show a direct relation between VLDL apoB overproduction and serum triglycerides and indicate a metabolically and biochemically coherent basis for familial combined hyperlipidemia. Arterioscler Thromb. 1993; 13 1110-1118
29 Gehrisch S, Kostka H, Tiebel M et al.. Mutations of the human hepatic lipase gene in patients with combined hypertriglyceridemia/hyperalphalipoproteinemia and in patients with familial combined hyperlipidemia. J Mol Med. 1999; 77 728-734
30 Cortner J A, Coates P M, Bennett M J, Cryer D R, Le N A. Familial combined hyperlipidemia: use of stable isotopes to demonstrate overproduction of very low-density lipoprotein apolipoprotein B by the liver. J Inherit Metab Dis. 1991; 14 915-922
31 Pajukanta P, Porkka K, Antikainen M et al.. No evidence of linkage between familial combined hyperlipidemia and genes encoding lipolytic enzymes in Finnish families. Arterioscler Thromb Vasc Biol. 1997; 17 841-850
32 Del Rincón-Jarero J P, Aguilar-Salinas C A, Guillén-Pineda L E, Gómez Pérez F J, Rull J A. Lack of agreement between the plasma lipid based criteria and the apoprotein B for the diagnosis of Familial Combined Hyperlipidemia (FCHL) in members of FCHL kindreds. Metabolism. 2002; 51 218-224
33 Wijsman E M, Brunzell J D, Jarvik G P, Austin M A, Motulsky A G, Deeb S S. Evidence against linkage of familial combined hyperlipidemia to the apolipoprotein AI-CIII-AIV gene complex. Arterioscler Thromb Vasc Biol. 1998; 18 215-226
34 Hopkins P, Heiss G, Ellison C et al.. Coronary artery disease in familial combined hyperlipidemia and familial hypertriglyceridemia. Circulation. 2003; 108 519-523
35 Aguilar-Salinas Carlos A, Olaiz G, Valles V et al.. High prevalence of low HDL cholesterol concentrations and mixed hyperlipidemia in a Mexican nation wide survey. J Lipid Res. 2001; 42 1298-1307
36 Austin M, McKnight B, Edward K et al.. Cardiovascular disease mortality in familial forms of hypertriglyceridemia: a 20 year prospective study. Circulation. 2000; 101 2777-2782
37 Purnell J, Kahn S, Schwartz R, Brunzell R. Relationship of insulin sensitivity and apoB levels to intraabdominal fat in subjects with familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol. 2001; 21 567-572
38 Aguilar-Salinas C A, Barrett H P, Pulai J, Zhu X, Schonfeld G. A familial combined hyperlipidemic kindred with impaired apolipoprotein B catabolism. Kinetics of apolipoprotein B during placebo and pravastatin therapy. Arterioscler Thromb Vasc Biol. 1997; 17 72-82
39 Chait A, Albers J J, Brunzell J D. Very low density overproduction in genetic forms of hypertriglyceridemia. Eur J Clin Invest. 1980; 10 161-172
40 Kissebah A H, Alfarsi A, Adams P W. Integrated regulation of very low density lipoprotein triglycerides and apolipoprotein B kinetics in man: normolipidemic subjects, familial hypertriglyceridemia and familial combined hyperlipidemia. Metabolism. 1981; 30 856-868
41 Allayee H, Dominguez K M, Aouizerat B E et al.. Contribution of the hepatic lipase gene to the atherogenic lipoprotein phenotype in familial combined hyperlipidemia. J Lipid Res. 2000; 41 245-252
42 Ayyobi A F, McGladdery S H, McNeely M J, Austin M A, Motulsky A G, Brunzell J D. Small, dense LDL and elevated apolipoprotein B are the common characteristics for the three major lipid phenotypes of familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol. 2003; 23 1289-1294
43 Vakkilainen J, Jauhiainen M, Yliatalo K et al.. LDL particle size in familial combined hyperlipidemia; effects of serum lipid, lipoprotein-modifying enzymes and lipid transfer proteins. J Lipid Res. 2002; 43 598-603
44 Pajukanta P, Terwilliger J D, Perola M et al.. Genomewide scan for familial combined hyperlipidemia genes in Finnish families, suggesting multiple susceptibility loci influencing triglyceride, cholesterol, and apolipoprotein B levels. Am J Hum Genet. 1999; 64 1453-1463
45 Tahvanainen E, Pajukanta P, Porkka K et al.. 1998. Haplotypes of the ApoA-I/C-III/A-IV gene cluster and familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol. 1998; 18 1810-1817
46 Pennacchio L A, Rubin E M. Apolipoprotein A5, a newly identified gene that affects plasma triglyceride levels in humans and mice. Arterioscler Thromb Vasc Biol. 2003; 23 529-534

Carlos Alberto Aguilar SalinasM.D.

Vasco de Quiroga 15, Mexico City 14000, Mexico